Official call identifier: HORIZON-HLTH-2026-01-TOOL-03
Objective of the call
This call aims to accelerate the transition from animal-based models to human-relevant New Approach Methodologies (NAMs) in biomedical research and regulatory testing.
It supports the development and validation of scalable platforms such as organoids, Organ-on-Chip systems and AI-based predictive models to improve disease modelling, drug discovery and chemical safety assessment.
The call also seeks to strengthen regulatory acceptance and promote FAIR data sharing through European infrastructures.
Scope of activities
Projects are expected to:
Eligible applicants
- Innovative SMEs, startups and enterprises aiming to scale and strengthen competitiveness
- Public-sector organisations driving transformation and societal impact
- Research and academic institutions commercialising knowledge
- Non-profit organisations delivering purpose-driven innovation
- Organisations based in EU Member States, EFTA/EEA, or Associated Countries (described in General Annex A, General Annex B, General Annex C)
- Minimum 3 independent partners from 3 eligible countries
Specific consortium we are looking for:
- Universities and biomedical research organisations
- Regulatory bodies and validation authorities
- Pharmaceutical, biotechnology and chemical industry partners
- Health research infrastructures and specialised SMEs
Eligible costs
Eligible costs follow standard Horizon Europe Research and Innovation Action (RIA) rules and include:
Funding conditions
Type of action:
Research and Innovation Action (RIA)
Funding rate:
100% of eligible costs
EU contribution per project:
Around EUR 7 million
Number of funded projects:
7 project
Project duration:
Typically 36 months
Technology Readiness Level (TRL):
Activities may start at any TRL
*Technology Readiness Levels (TRL) describe the maturity of a technology, from basic research (TRL 1) to fully deployed, market-ready solutions (TRL 9).
Deadline for submission
16 April 2026